Abstract | INTRODUCTION: AREAS COVERED: The EGFR signalling pathway and preclinical, Phase I and Phase II clinical studies on the pharmacokinetic, pharmacodynamic and safety evaluation of panitumumab are presented. Phase III studies utilising panitumumab in the first, second and third line setting in mCRC are also described. EXPERT OPINION:
Panitumumab exhibits excellent pharmacokinetics and pharmacodynamics by way of uncomplicated dosing, non-existent drug interactions, minimal infusion reactions and manageable side effects, making it a suitable target for combination treatments. However, innate and acquired resistances are still obstacles. To overcome this, experimented strategies are ongoing, particularly in patients with Her-2 and BRAF gene alterations. Novel biomarkers to improve patient selection and second-generation targeted antibodies are in development.
|
Authors | Louisa Lo, Dainik Patel, Amanda R Townsend, Timothy J Price |
Journal | Expert opinion on drug metabolism & toxicology
(Expert Opin Drug Metab Toxicol)
Vol. 11
Issue 12
Pg. 1907-24
( 2015)
ISSN: 1744-7607 [Electronic] England |
PMID | 26572750
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Panitumumab
- Cetuximab
|
Topics |
- Animals
- Antibodies, Monoclonal
(administration & dosage, pharmacokinetics, pharmacology)
- Antineoplastic Agents
(administration & dosage, pharmacokinetics, pharmacology)
- Cetuximab
(administration & dosage, pharmacology)
- Colorectal Neoplasms
(drug therapy, genetics, pathology)
- Disease-Free Survival
- Humans
- Molecular Targeted Therapy
- Panitumumab
- Patient Selection
- Survival Rate
|